Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy

被引：0
|
作者：
Lisha Wang
Sean R Williamson
Mingsheng Wang
Darrell D Davidson
Shaobo Zhang
Lee Ann Baldridge
Xiang Du
Liang Cheng
机构：
[1] Fudan University Shanghai Cancer Center,Department of Pathology
[2] Indiana University School of Medicine,Department of Pathology and Laboratory Medicine
[3] Henry Ford Health System,Department of Pathology and Laboratory Medicine
来源：
Molecular Cancer | / 13卷
关键词：
Kidney; Renal cell carcinoma; Metastasis; Targeted therapy; Molecular cytogenetics; Fluorescence in situ hybridization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma
    Park, Yong Hyun
    Jung, Jin-Woo
    Lee, Byung Ki
    Lee, Sangchul
    Jeong, Seong Jin
    Byun, Seok-Soo
    Lee, Sang Eun
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (02) : 153 - 157
  • [42] MOLECULAR-TARGETED THERAPY FOR ADVANCED RENAL CELL CARCINOMA
    Bracarda, Sergio
    Rossi, Marta
    Hamzay, Alketa
    Caserta, Claudia
    De Simone, Valeria
    Crino, Lucio
    [J]. ANTICANCER RESEARCH, 2008, 28 (5C) : 3217 - 3218
  • [43] An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases
    Semenescu, Liliana Eleonora
    Kamel, Amira
    Ciubotaru, Vasile
    Baez-Rodriguez, Silvia Mara
    Furtos, Mircea
    Costachi, Alexandra
    Dricu, Anica
    Tataranu, Ligia Gabriela
    [J]. CURRENT ISSUES IN MOLECULAR BIOLOGY, 2023, 45 (09) : 7680 - 7704
  • [44] Predictive factors of metastatic renal cell carcinoma in the era of molecular targeted therapy; A single institutional study
    Kondo, Hideyuki
    Shirotake, Suguru
    Okabe, Takashi
    Kaneko, Gou
    Nishimoto, Koshiro
    Oyama, Masafumi
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 : 258 - 258
  • [45] Hyponatremia Predicts the Inferior Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Molecular Targeted Therapy
    Kawashima, A.
    Takayama, H.
    Sato, M.
    Hatano, K.
    Fujita, K.
    Uemura, M.
    Nakai, Y.
    Nishimura, K.
    Tsujimura, A.
    Nonomura, N.
    [J]. UROLOGY, 2012, 80 (03) : S111 - S111
  • [46] Targeted drugs for metastatic renal cell carcinoma
    Motzer, Robert J.
    Basch, Ethan
    [J]. LANCET, 2007, 370 (9605): : 2071 - 2073
  • [47] Implications of therapy choice on overall survival in metastatic renal cell carcinoma
    Parmar, S
    Rademaker, AW
    Fung, BB
    Kozlowski, JM
    Kuzel, TM
    [J]. MEDICAL ONCOLOGY, 2005, 22 (04) : 399 - 405
  • [48] Prognostic relevance of the mTOR pathway in renal cell carcinoma - Implications for molecular patient selection for targeted therapy
    Pantuck, Allan J.
    Seligson, David B.
    Klatte, Tobias
    Yu, Hong
    Leppert, John T.
    Moore, Laurence
    O'Toole, Timothy
    Gibbons, Jay
    Belldegrun, Arie S.
    Figlin, Robert A.
    [J]. CANCER, 2007, 109 (11) : 2257 - 2267
  • [49] The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
    Yu, Xiaoteng
    Wang, Bing
    Li, Xuesong
    Lin, Gang
    Zhang, Cuijian
    Yang, Yang
    Fang, Dong
    Song, Yi
    He, Zhisong
    Zhou, Liqun
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [50] Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
    Dawsey, Scott J.
    Ornstein, Moshe C.
    [J]. CURRENT ONCOLOGY, 2021, 28 (06) : 5019 - 5024
12345